Cargando…
Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
CHAARTED was an ECOG-led phase III trial looking at early chemotherapy with the use of docetaxel in addition to androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer. The positive results of the trial showing marked improvement in overall survival in those who rece...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854101/ https://www.ncbi.nlm.nih.gov/pubmed/26510505 http://dx.doi.org/10.4103/1008-682X.164920 |